Antiviral Research, Craig R Rayner, Karen Yeo, David Wesche, Lisa Almond, Michael Dodds, Patrick F Smith, Mark Sullivan
Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre -including this research content -immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
References
Baraka, Ivermectin distribution in the plasma and tissues of patients infected with Onchocerca volvulus, Eur. J. Clin. Pharmacol
Crump, Omura, Ivermectin, 'wonder drug' from Japan: the human use perspective, Proc. Jpn. Acad. Ser. B Phys. Biol. Sci
Guzzo, Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects, J. Clin. Pharmacol
Jans, Kylie, Caly, Druce, Catton et al., The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antiviral Res
Merck, None, Mectizan NDA
Merck, Stromectol USPI
Navarro, Camprubí, Requena-Méndez, Buonfrate, Giorli et al., Safety of high-dose ivermectin: a systematic review and meta-analysis, J. Antimicrob. Chemother
Noël, Lima, Pharmacological aspects and clues for the rationale use of Chloroquine/Hydroxychloroquine facing the therapeutic challenges of COVID-19 pandemic, Lat. Am. J. Clin. Sci. Med. Technol
Pimenta, Silva, Noël, Ivermectin is a nonselective inhibitor of mammalian P-type ATPases, Naunyn-Schmied Arch. Pharmacol
Smit, Ochomo, Waterhouse, Kwambai, Abong'o et al., Pharmacokinetics-pharmacodynamics of high dose ivermectin with Dihydroartemisinin-piperaquine on mosquitocidal activity and QT-prolongation (IVERMAL), Clin. Pharmacol. Ther
Smit, Pharmacokinetics-pharmacodynamics of high-dose ivermectin with dihydroartemisinin-piperaquine on mosquitocidal activity and QT-prolongation (IVERMAL), Clin. Pharmacol. Ther
Tay, Fraser, Chan, Moreland, Rathore et al., Nuclear localization of dengue virus (DENV) 1-4 non-structural protein 5; protection against all 4 DENV serotypes by the inhibitor Ivermectin, Antivir. Res,
doi:10.1016/j.2013SepYang, Atkinson, Wang, Lee, Bogoyevitch et al., The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer
Yao, In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Clin. Infect. Dis
DOI record:
{
"DOI": "10.1016/j.antiviral.2020.104805",
"ISSN": [
"0166-3542"
],
"URL": "http://dx.doi.org/10.1016/j.antiviral.2020.104805",
"alternative-id": [
"S0166354220302199"
],
"article-number": "104805",
"assertion": [
{
"label": "This article is maintained by",
"name": "publisher",
"value": "Elsevier"
},
{
"label": "Article Title",
"name": "articletitle",
"value": "Ivermectin and COVID-19: A report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors' responses"
},
{
"label": "Journal Title",
"name": "journaltitle",
"value": "Antiviral Research"
},
{
"label": "CrossRef DOI link to publisher maintained version",
"name": "articlelink",
"value": "https://doi.org/10.1016/j.antiviral.2020.104805"
},
{
"label": "Content Type",
"name": "content_type",
"value": "simple-article"
},
{
"label": "Copyright",
"name": "copyright",
"value": "© 2020 Published by Elsevier B.V."
}
],
"author": [
{
"affiliation": [],
"family": "Bray",
"given": "Mike",
"sequence": "first"
},
{
"affiliation": [],
"family": "Rayner",
"given": "Craig",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Noël",
"given": "François",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Jans",
"given": "David",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Wagstaff",
"given": "Kylie",
"sequence": "additional"
}
],
"container-title": "Antiviral Research",
"container-title-short": "Antiviral Research",
"content-domain": {
"crossmark-restriction": true,
"domain": [
"elsevier.com",
"sciencedirect.com"
]
},
"created": {
"date-parts": [
[
2020,
4,
21
]
],
"date-time": "2020-04-21T15:26:55Z",
"timestamp": 1587482815000
},
"deposited": {
"date-parts": [
[
2020,
6,
13
]
],
"date-time": "2020-06-13T00:44:34Z",
"timestamp": 1592009074000
},
"indexed": {
"date-parts": [
[
2024,
5,
3
]
],
"date-time": "2024-05-03T08:27:46Z",
"timestamp": 1714724866712
},
"is-referenced-by-count": 87,
"issued": {
"date-parts": [
[
2020,
6
]
]
},
"language": "en",
"license": [
{
"URL": "https://www.elsevier.com/tdm/userlicense/1.0/",
"content-version": "tdm",
"delay-in-days": 0,
"start": {
"date-parts": [
[
2020,
6,
1
]
],
"date-time": "2020-06-01T00:00:00Z",
"timestamp": 1590969600000
}
}
],
"link": [
{
"URL": "https://api.elsevier.com/content/article/PII:S0166354220302199?httpAccept=text/xml",
"content-type": "text/xml",
"content-version": "vor",
"intended-application": "text-mining"
},
{
"URL": "https://api.elsevier.com/content/article/PII:S0166354220302199?httpAccept=text/plain",
"content-type": "text/plain",
"content-version": "vor",
"intended-application": "text-mining"
}
],
"member": "78",
"original-title": [],
"page": "104805",
"prefix": "10.1016",
"published": {
"date-parts": [
[
2020,
6
]
]
},
"published-print": {
"date-parts": [
[
2020,
6
]
]
},
"publisher": "Elsevier BV",
"reference-count": 0,
"references-count": 0,
"relation": {},
"resource": {
"primary": {
"URL": "https://linkinghub.elsevier.com/retrieve/pii/S0166354220302199"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subject": [],
"subtitle": [],
"title": "Ivermectin and COVID-19: A report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors' responses",
"type": "journal-article",
"update-policy": "http://dx.doi.org/10.1016/elsevier_cm_policy",
"volume": "178"
}
